Henry Schein (NASDAQ:HSIC) Lowered to “Hold” Rating by Wall Street Zen

Henry Schein (NASDAQ:HSIC) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.

Several other brokerages have also weighed in on HSIC. Robert W. Baird set a $97.00 price objective on Henry Schein in a report on Wednesday, May 6th. BMO Capital Markets began coverage on Henry Schein in a report on Wednesday. They issued a “market perform” rating and a $85.00 price objective for the company. BTIG Research upgraded Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Thursday, June 11th. UBS Group reaffirmed a “neutral” rating and set a $85.00 price objective (down from $87.00) on shares of Henry Schein in a report on Wednesday, May 6th. Finally, Mizuho cut their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Henry Schein has a consensus rating of “Hold” and a consensus target price of $87.64.

Henry Schein Stock Performance

HSIC stock traded up $0.54 during mid-day trading on Friday, hitting $84.40. The company had a trading volume of 1,156,510 shares, compared to its average volume of 1,187,323. The firm has a market cap of $9.61 billion, a PE ratio of 25.50, a price-to-earnings-growth ratio of 1.63 and a beta of 0.81. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. Henry Schein has a 12 month low of $61.94 and a 12 month high of $89.29. The stock’s fifty day moving average price is $78.04 and its two-hundred day moving average price is $77.34.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. During the same period in the prior year, the firm earned $1.15 EPS. The company’s revenue was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, analysts forecast that Henry Schein will post 5.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director William K. Daniel acquired 10,000 shares of Henry Schein stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $69.19 per share, with a total value of $691,900.00. Following the completion of the purchase, the director owned 20,000 shares in the company, valued at approximately $1,383,800. The trade was a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.89% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Canvas Wealth Advisors LLC bought a new position in shares of Henry Schein in the second quarter worth $201,000. Contravisory Investment Management Inc. purchased a new position in Henry Schein during the second quarter worth about $84,000. Breakwater Capital Group purchased a new position in Henry Schein during the second quarter worth about $200,000. Beacon Investment Advisory Services Inc. increased its stake in Henry Schein by 7.7% in the 2nd quarter. Beacon Investment Advisory Services Inc. now owns 9,709 shares of the company’s stock worth $811,000 after acquiring an additional 696 shares during the last quarter. Finally, Czech National Bank raised its holdings in shares of Henry Schein by 1.1% in the 2nd quarter. Czech National Bank now owns 27,561 shares of the company’s stock valued at $2,302,000 after acquiring an additional 308 shares in the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.